Table 2. Concentrations of Core AD Biomarkers in CSF at Baseline in the Clinical Groups.
| Characteristic | Median (range), pg/mL | |||
|---|---|---|---|---|
| Control group | AD group | AD-MCI group | AD-dementia group | |
| DDI study cohort | ||||
| No. | 63 | 77 | 72 | 5 |
| CSF | ||||
| Aβ42 | 1090.0 (720.0-1880.0) | 535.0 (250.0-706.0)a | 537.5 (250.0-706.0)a | 413.0 (370.0-600.0)a |
| T-tau | 294.0 (102.0-1050.0) | 520.0 (60.0-1670.0)a | 502.0 (60.0-1370.0)a | 1040.0 (507.0-1670.0)a,b |
| P-tau | 48.0 (27.0-134.0) | 75.7 (23.0-196.0)a | 74.0 (23.0-177.0)a | 134.0 (67.0-196.0)a |
| Trønderbrain cohort | ||||
| No. | 54 | 49 | 30 | 19 |
| CSF | ||||
| Aβ42 | 1054.6 (665.8-1674.1) | 447.4 (173.0-611.6)a | 433.0 (173.0-602.6)a | 476.8 (322.1-611.6)a |
| T-tau | 272.6 (137.5-665.9) | 515.5 (135.4-2325.3)a | 438.4 (135.4-2325.3)a | 624.2 (221.9-1391.0)a |
| P-tau | 51.9 (32.8-86.4) | 76.4 (15.9-168.8)a | 71.9 (13.9-168.8)a | 80.4 (35.9-156.9)a |
Abbreviations: Aβ42, amyloid-β 42; AD, Alzheimer disease; AD-MCI, AD with mild cognitive impairment; CSF, cerebrospinal fluid; DDI, Dementia Disease Initiation; P-tau, phosphorylated tau; T-tau, total tau.
a
P < .01 compared with control group.
b
P < .05 compared with AD-MCI group.